OncoMatch/Clinical Trials/NCT06959511
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
Is NCT06959511 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Zanzalintinib for neoadjuvant treatment.
Treatment: Zanzalintinib — To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.
Check if I qualifyExtracted eligibility criteria
Cancer type
Thyroid Cancer
Biomarker criteria
Required: RET germline mutation
Medullary thyroid cancer participants with germline RET or known somatic RET mutations [excluded]
Required: RET somatic mutation
Medullary thyroid cancer participants with germline RET or known somatic RET mutations [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: zanzalintinib (zanzalintinib)
Prior treatment with zanzalintinib
Cannot have received: tyrosine kinase inhibitor
Prior treatment with a tyrosine kinase inhibitor
Cannot have received: cytotoxic chemotherapy
Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment
Cannot have received: biologic therapy
Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment
Cannot have received: systemic anticancer therapy
Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment
Cannot have received: radiation therapy
Exception: bone metastasis within 2 weeks, any other radiation therapy within 4 weeks, systemic radionuclides within 6 weeks
Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment.
Lab requirements
Blood counts
ANC ≥ 1500/mm3 without G-CSF support; platelets ≥ 100,000/mm3 without transfusion; hemoglobin ≥9 g/dL without transfusion; INR ≤ 1.5; aPTT ≤ 1.2 x ULN; UPCR ≤1 mg/mg
Kidney function
Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 40 mL/min
Liver function
ALT, AST, and ALP ≤ 3 x ULN (≤5 x ULN for ALP with bone metastasis); total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert's disease)
Cardiac function
QTcF ≤ 480 ms within 14 days per ECG before first dose
Adequate organ and marrow function, based upon meeting all the following laboratory criteria within 28 days before first dose of study treatment: ... Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms within 14 days per electrocardiogram (ECG) before first dose of study treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify